User:Mr. Ibrahem/Tivozanib

Mr. Ibrahem/Tivozanib
Clinical data
Trade names	Fotivda
Other names	AV-951
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Tivozanib;
Routes of; administration	By mouth
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	>99%
Elimination half-life	4.5–5.1 days
Excretion	79% faeces, 12% urine
Chemical and physical data
Formula	C22H19ClN4O5
Molar mass	454.87 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1noc(c1)C)Nc4ccc(Oc2c3cc(OC)c(OC)cc3ncc2)cc4Cl;
	InChI InChI=InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28); Key:SPMVMDHWKHCIDT-UHFFFAOYSA-N;

Tivozanib, sold under the brand name Fotivda, is a medication used to treat renal cell carcinoma (RCC).^[1] Specifically it is used for advanced disease which has failed other treatments.^[1] It is taken by mouth.^[1]

Common side effects include tiredness, high blood pressure, diarrhea, nausea, change in voice, low thyroid, cough, and mouth inflammation.^[1] Other side effects may include low sodium, heart problems, blood clots, bleeding, and increased lipase.^[1] Use in pregnancy may harm the baby.^[1] It is a VEGF receptor tyrosine kinase inhibitor, which blocks the formation of new blood vessels.^[3]^[1]

Tivozanib was approved for medical use in Europe in 2017 and the United States in 2021.^[3]^[1] In the United States 4 weeks of treatment costs about 26,000 USD.^[4]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Fotivda- tivozanib capsule". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021. {{cite web}}: More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help)
^ "FDA approves tivozanib for relapsed or refractory advanced renal cell". U.S. Food and Drug Administration. 10 March 2021. Archived from the original on 11 March 2021. Retrieved 16 March 2021. {{cite web}}: More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help) This article incorporates text from this source, which is in the public domain.
^ ^a ^b ^c ^d "Fotivda EPAR". European Medicines Agency (EMA). Archived from the original on 13 May 2021. Retrieved 16 March 2021. {{cite web}}: More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help)
^ "Tivozanib". Archived from the original on 31 October 2022. Retrieved 31 October 2022. {{cite web}}: More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help)

[PI2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Fotivda- tivozanib capsule". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021. {{cite web}}: More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help)

[FDA_tivozanib-2] "FDA approves tivozanib for relapsed or refractory advanced renal cell". U.S. Food and Drug Administration. 10 March 2021. Archived from the original on 11 March 2021. Retrieved 16 March 2021. {{cite web}}: More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help) This article incorporates text from this source, which is in the public domain.

[EPAR2022-3] "Fotivda EPAR". European Medicines Agency (EMA). Archived from the original on 13 May 2021. Retrieved 16 March 2021. {{cite web}}: More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help)

[4] "Tivozanib". Archived from the original on 31 October 2022. Retrieved 31 October 2022. {{cite web}}: More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help)

[1]

[2]

[3]

[4]